| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3810/HP.2014.08.1122 |
| P698 | PubMed publication ID | 25255411 |
| P2093 | author name string | Stephen Brunton | |
| Timothy S Reid | |||
| P2860 | cites work | First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus | Q21195757 |
| Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 | ||
| Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data | Q30612949 | ||
| SGLT2 inhibition--a novel strategy for diabetes treatment | Q34117872 | ||
| Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications | Q34120717 | ||
| Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes | Q34227891 | ||
| Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise | Q34646948 | ||
| Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial | Q34804900 | ||
| Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. | Q35011476 | ||
| Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis | Q36578983 | ||
| Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease | Q36845771 | ||
| Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial | Q37106527 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes | Q37193454 | ||
| Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial | Q37278239 | ||
| Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial | Q37302078 | ||
| Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications | Q37439364 | ||
| Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 | ||
| Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. | Q37645623 | ||
| Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes | Q37692849 | ||
| Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus | Q37703184 | ||
| Biology of human sodium glucose transporters | Q37870037 | ||
| Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. | Q37878715 | ||
| The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. | Q37940036 | ||
| Canagliflozin: a review of its use in patients with type 2 diabetes mellitus | Q38212007 | ||
| Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus | Q38439475 | ||
| Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor | Q43599025 | ||
| Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial | Q43804231 | ||
| Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies | Q44438668 | ||
| Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial | Q44452805 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
| Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia | Q45442620 | ||
| Renal glucose excretion and tubular reabsorption rate related to blood glucose in subjects with type 2 diabetes with a critical reappraisal of the "renal glucose threshold" model. | Q46024197 | ||
| Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin | Q46401612 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea | Q46458866 | ||
| Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes | Q46818617 | ||
| Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial | Q47909934 | ||
| Urinary tract infections in patients with diabetes treated with dapagliflozin | Q48016891 | ||
| Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. | Q50996678 | ||
| Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. | Q51333570 | ||
| Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. | Q51359456 | ||
| Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. | Q51362851 | ||
| Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. | Q51372081 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. | Q51468797 | ||
| Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp study. | Q51943358 | ||
| From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus | Q57479460 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 96-108 | |
| P577 | publication date | 2014-08-01 | |
| P1433 | published in | Hospital Practice | Q5908551 |
| P1476 | title | Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes | |
| P478 | volume | 42 |
| Q33665173 | Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy |
| Q38573559 | Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus |
| Q55407978 | Characterization of Metabolic Parameters in Responders and Nonresponders Treated with Canagliflozin Monotherapy in Drug-naive Subjects with Type 2 Diabetes. |
| Q57462258 | Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes |
| Q26786524 | What's next after metformin? focus on sulphonylurea: add-on or combination therapy |
Search more.